CNBX Pharmaceuticals Net Loss Widens to $157,817 in First Half of Fiscal 2026

CNBX Pharmaceuticals Inc., a pharmaceutical company, reported a net loss of $157,817 for the six months ending February 28, 2026, compared to a net loss of $104,140 in the same period a year earlier, representing a 52% increase in losses. The company generated no revenue during either period. Read more earnings reports.

General and administrative expenses rose to $136,965 for the six months ending February 28, 2026, up 35% from $101,580 in the prior-year period. The company reported no research and development expenses or cost of services during the period.

For the three months ending February 28, 2026, CNBX posted a net loss of $44,098, down 37% from a loss of $69,788 in the same quarter last year. General and administrative expenses for the quarter totaled $72,963, compared to $64,743 a year earlier.

Financial loss for the six-month period was $20,852, compared to a loss of $2,560 in the prior year. The company's cash position declined to $12,154 at February 28, 2026, down from $15,111 at August 31, 2025.

The company's balance sheet showed total current liabilities of $2,548,447 at February 28, 2026, including $1,090,370 in convertible loans, $75,000 in short-term loans, and $1,339,547 due to a related party. Stockholders' deficit stood at $2,533,548, compared to a deficit of $2,496,293 six months earlier.

During the six months, CNBX converted $120,562 of convertible loans into 571,805,889 shares of common stock. Total outstanding shares increased to 1,125,768,095 at February 28, 2026, from 553,962,206 at August 31, 2025.

Cash used in operating activities totaled $77,957 for the six months, compared to $90,741 in the prior-year period. The company raised $75,000 from a short-term loan during the period, compared to $110,000 in the same period last year.